To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

INCLUSION CRITERIA * Women at least 18 years of age. * Meet ACR criteria for diagnosis of SLE. * Concomitant treatment with prednisone at a dose of ≥5 mg/day over the last 30 days prior to Screening visit. * Cumulative history of oral glucocorticoid use for at least 6 months over the last year prior to the Screening Visit (the 6 months do not have to be consecutive). * Patient has lumbar spine and proximal femur anatomy suitable for measurement by DXA with at least 3 evaluable vertebrae from L1 to L4. * SLEDAI ≥3 at the Qualifying Visit. * Women of child-bearing potential must have a negative serum pregnancy test (at the Screening Visit) and agree to use a reliable form of birth control while participating in the study. * Patient is fully ambulatory. * Patient has read and signed an Informed Consent Form. EXCLUSION CRITERIA * History of breast cancer or malignancy of the reproductive tract organs. * History of any other cancers unless no evidence of disease for 5 years. * History of endometrial hyperplasia. * End stage renal disease or receiving hemodialysis treatment. * Any disease or condition that would preclude the accurate measurement of bone mineral density of the lumbar spine or proximal femur by dual X-ray absorptiometry. * A T-score of less than or equal to - 2.5 of the L-spine or proximal femur at Screening DXA assessment. * Unstable cardiac disease. * Conditions causing bone loss such as hyperparathyroidism, Cushing's disease, thyrotoxicosis, chronic diarrheal state or malabsorption, renal tubular acidosis, or anorexia nervosa. * Significant hepatic disease (i.e., cirrhosis). * Body mass index \> 35 kg/m2 or weight \>300 lbs. * Patients who are pregnant or breast feeding. * Patients who require glucocorticoids by an alternate day dosing schedule. * Known hypersensitivity to DHEA, or the inactive ingredients used in the GL701 formulation (cornstarch, lactose, magnesium stearate). * Known medical contraindication or hypersensitivity to Calcium/Vitamin D. * Participation in any prior DHEA or GL701 study. * Use of investigational agents within 30 days of the Screening Visit or 10 half-lives of the agent. * Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease). * The patient is taking or has taken one of the medications listed below: ANTIRESORPTIVES: * Use of calcitonin within 30 days prior to Screening Visit. * Fluorides \> 1 mg/day at any time prior to the study. * Strontium at pharmacologic dose at any time. BISPHOSPHONATE USE as follows: * Any use within 90 days prior to the Screening Visit. * ≥ 2 weeks of use in the last year prior to the Screening Visit. * ≥ 3 months of use in the last 2 years prior to the Screening Visit. * ≥ 1 intravenous dose over the last 2 years prior to the Screening Visit. * ≥ 6 months of life-time exposure prior to the Screening Visit. ESTROGENIC STEROIDS (Except for oral contraceptives): * Estrogenic steroids (HRT) within 60 days of the Screening Visit. * Selective estrogen receptor modulator (raloxifene) within 60 days of the Screening Visit. OTHER HORMONES: * Parathyroid hormone (PTH) within six months of the Screening Visit. * Use of any androgens, including prescription or nutritional supplement DHEA, within 30 days of the Screening Visit.